These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25874820)

  • 1. Potential Synergy of Radiation Therapy With Vismodegib for Basal Cell Carcinoma.
    Strasswimmer JM
    JAMA Dermatol; 2015 Sep; 151(9):925-6. PubMed ID: 25874820
    [No Abstract]   [Full Text] [Related]  

  • 2. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
    Pollom EL; Bui TT; Chang AL; Colevas AD; Hara WY
    JAMA Dermatol; 2015 Sep; 151(9):998-1001. PubMed ID: 25874733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin.
    Gathings RM; Orscheln CS; Huang WW
    J Am Acad Dermatol; 2014 Apr; 70(4):e88-e89. PubMed ID: 24629372
    [No Abstract]   [Full Text] [Related]  

  • 4. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib.
    Iarrobino A; Messina JL; Kudchadkar R; Sondak VK
    J Am Acad Dermatol; 2013 Jul; 69(1):e33-4. PubMed ID: 23768306
    [No Abstract]   [Full Text] [Related]  

  • 5. Induction Hedgehog pathway inhibition followed by combined-modality radiotherapy for basal cell carcinoma.
    Raleigh DR; Algazi A; Arron ST; Neuhaus IM; Yom SS
    Br J Dermatol; 2015 Aug; 173(2):544-6. PubMed ID: 25702621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
    Papastefanou VP; René C
    Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.
    Brinkhuizen T; Reinders MG; van Geel M; Hendriksen AJ; Paulussen AD; Winnepenninckx VJ; Keymeulen KB; Soetekouw PM; van Steensel MA; Mosterd K
    J Am Acad Dermatol; 2014 Nov; 71(5):1005-8. PubMed ID: 25199678
    [No Abstract]   [Full Text] [Related]  

  • 8. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
    Kwon GP; Ally MS; Bailey-Healy I; Oro AE; Kim J; Chang AL; Aasi S; Tang JY
    J Am Acad Dermatol; 2016 Jul; 75(1):213-5. PubMed ID: 27317518
    [No Abstract]   [Full Text] [Related]  

  • 9. Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck : First clinical experience with vismodegib for locally advanced disease.
    Schulze B; Meissner M; Ghanaati S; Burck I; Rödel C; Balermpas P
    Strahlenther Onkol; 2016 Jan; 192(1):25-31. PubMed ID: 26449347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib.
    Zargari O; Azimi SZ; Geranmayeh S
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28631369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.
    Wolfe CM; Green WH; Cognetta AB; Hatfield HK
    Dermatol Surg; 2012 Nov; 38(11):1863-6. PubMed ID: 22805146
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug hypersensitivity syndrome in a patient receiving vismodegib.
    Lam T; Wolverton SE; Davis CL
    J Am Acad Dermatol; 2014 Mar; 70(3):e65-6. PubMed ID: 24528922
    [No Abstract]   [Full Text] [Related]  

  • 13. Vismodegib in advanced basal-cell carcinoma.
    Babacan T; Sarici F; Altundag K
    N Engl J Med; 2012 Sep; 367(10):969-70; author reply 970. PubMed ID: 22931270
    [No Abstract]   [Full Text] [Related]  

  • 14. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 15. Vismodegib and surgery combined - effective treatment of locally advanced basal cell carcinoma.
    Paulsen JF; Øregaard JS; Nielsen AL; Gehl J; Venzo A
    Acta Oncol; 2016 Dec; 55(12):1492-1494. PubMed ID: 27448604
    [No Abstract]   [Full Text] [Related]  

  • 16. Indications and limitations of vismodegib for basal cell carcinoma.
    Yin VT; Sniegowski M; Esmaeli B
    JAMA Ophthalmol; 2014 Jul; 132(7):905-6. PubMed ID: 25010179
    [No Abstract]   [Full Text] [Related]  

  • 17. Indications and limitations of vismodegib for basal cell carcinoma--reply.
    Gill HS; Moscato EE; Silkiss RZ
    JAMA Ophthalmol; 2014 Jul; 132(7):906. PubMed ID: 25010181
    [No Abstract]   [Full Text] [Related]  

  • 18. Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.
    Kaehler KC; Gutzmer R; Egberts F; Hauschild A
    J Dtsch Dermatol Ges; 2014 Oct; 12(10):906-7. PubMed ID: 25041591
    [No Abstract]   [Full Text] [Related]  

  • 19. Vismodegib resistance in basal cell carcinoma: not a smooth fit.
    Ridky TW; Cotsarelis G
    Cancer Cell; 2015 Mar; 27(3):315-6. PubMed ID: 25759014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vismodegib in metastasized basal cell carcinoma].
    Reinders MG; Dirix L; Mosterd K; van Doorn R
    Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.